ResMed Inc (RMD)
ResMed Inc (RMD) carries a ŷRobot AI score of 58 out of 100. The model's fair value estimate is $240.85, 0.6% above the last close of $239.50. The chart signal reads Sell.
| Metric | RMD |
|---|---|
| AI score | 58 / 100 |
| Chart signal | Sell |
| Fair value estimate | $240.85 |
| Upside to fair value | 0.6% |
| Previous close | $239.50 |
| P/E | 24.24 |
| Price / sales | 5.71 |
| Market cap | $33.55B |
| EPS | 10.43 |
| Revenue growth | 9.6% |
| 1-year price change | -0.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about RMD
Is RMD overvalued or undervalued right now?
As of Oct 31, 2026, ŷRobot's fair-value model estimates ResMed Inc (RMD) at $240.85 against a last close of $239.50, implying 0.6% upside to the model's estimate.
Is RMD's chart signal bullish or bearish?
The chart-signal model classifies RMD as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is RMD's ŷRobot AI score?
RMD scores 58 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is RMD stock expensive on P/E and P/S?
RMD trades at 24.2 times earnings and 5.7 times sales as of Nov 13, 2026.
What does RMD's seasonal forecast show?
ŷRobot's seasonal forecast curve for RMD reads +0.6% at 30 days, +0.6% at 90 days, and -0.4% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is RMD growing?
ResMed Inc's revenue growth is +9.6% and free-cash-flow growth is +1.4% on the latest reported figures.
RMD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.